News and Announcements
Kazia Therapeutics CEO featured in the Australian Financial Review
- Published August 20, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia’s Therapeutics Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.
In the interview, Dr Garner spoke about the importance of networks and collaborations in the biotech industry and how Kazia focuses on structuring and managing the approvals and trial stages of drug development.
The article also talks about the five ongoing trials with Kazia’s lead candidate, GDC-0084 and our recent announcement that leading US cancer treatment centre, Memorial Sloan Kettering (MSK), will use GDC-0084 in a phase I clinical trial for cancer that has spread to the brain (brain metastases).
Read the article here.
Interview with Proactive Investors
Also recently, Dr Garner also discussed the ongoing clinical program with GDC-0084 and the completion of recruitment for Part B of the Cantrixil trial in an interview with Proactive Investors.
In the interview, Dr Garner also discusses:
• Kazia’s strategy with GDC-0084
• How equity market volatility impacts Kazia
• The upcoming milestones and value catalysts for the company
Watch the video interview here.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
